

FOI 4057

**Dermatology and Rheumatology Treatment**

**Q1. How many new patients were treated for any condition by the Trusts Dermatology Department in the latest 3-month period of January, February and March 2026 (or the latest 3 months available) with the treatments I have provided below?**

**If you are able to, provide the split of new patients who received their treatment for Psoriasis.**

**Define a "new patient" as a patient who is receiving any of the treatments listed below for the first time. If a patient received any of the below treatments in 2024 or previous years, they can be classed as a new patient for this period.**

	<b>Total Dermatology Department</b>	<b>Psoriasis</b>
Adalimumab [Humira]	0	0
Adalimumab [All Biosimilars]	2	2
Apremilast [Otezla]	0	0
Apremilast [Generic]	0	0
Etanercept [Enbrel]	0	0
Etanercept [All Biosimilars]	0	0
Infliximab [Remicade]	0	0
Infliximab [All Biosimilars]	0	0
Ustekinumab [Stelara]	0	0
Ustekinumab [All Biosimilars]	4	4
Bimekizumab [Bimzelx]	1	1
Brodalumab [Kyntheum]	0	0
Certolizumab [Cimzia]	0	0
Deucravacitinib [Sotyktu]	0	0
Dimethyl Fumarate [Skilarence]	0	0

Guselkumab [Tremfya]	0	0
Ixekizumab [Taltz]	0	0
Risankizumab [Skyrizi]	1	1
Secukinumab [Cosentyx]	3	0
Spesolimab [Spevigo]	0	0
Tildrakizumab [Illumetri]	0	0

**Q2. How many new patients were treated for any condition by the Trusts Rheumatology Department in the latest 3-month period of January, February and March 2026 (or the latest 3 months available) with the treatments I have provided below?**

**If you are able to, provide the split of new patients who received their treatment for Axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA).**

	Total Rheumatology Department	Axial Spondylorarthritis (axSpA)	Rheumatoid Arthritis (RA)	Psoriatic Arthritis (PsA)
Abatacept [Orencia]	3	0	3	0
Adalimumab [Humira]	0	0	0	0
Adalimumab [All Biosimilars]	43	5	22	16
Apremilast [Otezla]	0	0	0	0
Apremilast [Generic]	0	0	0	0
Baricitinib [Olumiant]	1	0	1	0
Bimekizumab [Bimzelx]	13	1	0	12
Certolizumab [Cimzia]	10	2	0	8
Etanercept [Enbrel]	0	0	0	0
Etanercept [All Biosimilars]	24	1	18	5
Filgotinib [Jyseleca]	0	0	0	0



Golimumab [Simponi]	0	0	0	0
Golimumab [All Biosimilars]	1	0	1	0
Guselkumab [Tremfya]	5	0	0	5
Infliximab [Remicade]	0	0	0	0
Infliximab [All Biosimilars]	5	1	1	3
Ixekizumab [Taltz]	8	2	0	6
Risankizumab [Skyrizi]	0	0	0	0
Rituximab [MabThera]	0	0	0	0
Rituximab [Biosimilars]	1	0	1	0
Sarilumab [Kevzara]	0	0	0	0
Secukinumab [Cosentyx]	18	6	1	11
Tocilizumab [RoActemra]	11	0	9	0
Tocilizumab [Biosimilars]	0	0	0	0
Tofacitinib [Xeljanz]	0	0	0	0
Upadacitinib [Rinvoq]	15	3	9	3
Ustekinumab [Stelara]	0	0	0	0
Ustekinumab Biosimilar	0	0	0	0